In contrast to the EGFR mutation residing in the intracellular kinase domain in lung cancer, gliomas harbor EGFR mutations in the extracellular domain, and this signature of EGFR alteration gave the explanation to the dismal effect on the treatment with Tyrosine kinase inhibitors (TKIs) such as erlotinib [17]. Here, EGFR is linked to lung cancer.